肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：AZD5363治疗实体肿瘤，PIK3CA突变乳腺癌和妇科恶性肿瘤

2018-05-09 MedSci MedSci原创

AZD5363实体肿瘤乳腺癌妇科肿瘤
关注

CLIN CANCER RES近期发表了一篇文章，报道了选择性pan-AKT抑制剂AZD5363治疗晚期实体肿瘤的临床试验结果。该研究的目的是评估AZD5363的安全性，耐受性和药代动力学，评估其初步的临床效果。

CLIN CANCER RES近期发表了一篇文章，报道了选择性pan-AKT抑制剂AZD5363治疗晚期实体肿瘤的临床试验结果。该研究的目的是评估AZD5363的安全性，耐受性和药代动力学，评估其初步的临床效果。

研究纳入≥18岁的患者。分为连续给药，间断给药{4天/周（4/7），2天/周（2/7）}，同时进行安全性，药代动力学和药效学研究。拓展队列由约20例患者构成，研究AZD5363在PIK3CA突变乳腺癌和妇科肿瘤中的作用。研究结果表明，连续给药组最大耐受剂量为320mg，间断给药（4/7）最大耐受剂量为480mg，间断给药（2/7）的最大耐受剂量为640mg。连续给药的剂量限制毒性为皮疹和腹泻，2/7组为高血糖，4/7组无剂量限制毒性。常见的不良反应为腹泻和恶心。在PIK3CA突变乳腺癌和妇科肿瘤拓展队列使用推荐Ⅱ期剂量（480mg bid，4/7间断），分别有46%和56%的患者出现肿瘤缩小，RECIST反应分别为4%和8%。这些反应低于预期的20%，因此未进行进一步的PIK3CA突变队列的研究。

文章最后认为，使用推荐Ⅱ期剂量时，AZD5363耐受性良好且对肿瘤具有稳定的控制效果。

原始出处：

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1653795, encodeId=4e7d1653e95e8, content=<a href='/topic/show?id=b374448088f' target=_blank style='color:#2F92EE;'>#妇科恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44808, encryptionId=b374448088f, topicName=妇科恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=840a24370605, createdName=lfcmxl, createdTime=Tue Dec 11 12:16:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007516, encodeId=0e9f200e51647, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 28 06:16:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714783, encodeId=05861e1478304, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Thu Jun 07 13:16:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780265, encodeId=b93c1e8026509, content=<a href='/topic/show?id=d8e13080cf' target=_blank style='color:#2F92EE;'>#AZD5363#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3080, encryptionId=d8e13080cf, topicName=AZD5363)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec37461, createdName=szhvet, createdTime=Fri Sep 28 11:16:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710575, encodeId=c57b1e105757f, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Nov 04 23:16:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379156, encodeId=d9a813e91561e, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Fri May 11 11:16:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313901, encodeId=ce3831390188, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Thu May 10 21:59:31 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313758, encodeId=6c18313e580d, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu May 10 08:16:04 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-12-11 lfcmxl

    #妇科恶性肿瘤#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1653795, encodeId=4e7d1653e95e8, content=<a href='/topic/show?id=b374448088f' target=_blank style='color:#2F92EE;'>#妇科恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44808, encryptionId=b374448088f, topicName=妇科恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=840a24370605, createdName=lfcmxl, createdTime=Tue Dec 11 12:16:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007516, encodeId=0e9f200e51647, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 28 06:16:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714783, encodeId=05861e1478304, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Thu Jun 07 13:16:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780265, encodeId=b93c1e8026509, content=<a href='/topic/show?id=d8e13080cf' target=_blank style='color:#2F92EE;'>#AZD5363#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3080, encryptionId=d8e13080cf, topicName=AZD5363)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec37461, createdName=szhvet, createdTime=Fri Sep 28 11:16:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710575, encodeId=c57b1e105757f, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Nov 04 23:16:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379156, encodeId=d9a813e91561e, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Fri May 11 11:16:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313901, encodeId=ce3831390188, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Thu May 10 21:59:31 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313758, encodeId=6c18313e580d, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu May 10 08:16:04 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-11-28 xinmeili

    #PIK3CA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1653795, encodeId=4e7d1653e95e8, content=<a href='/topic/show?id=b374448088f' target=_blank style='color:#2F92EE;'>#妇科恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44808, encryptionId=b374448088f, topicName=妇科恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=840a24370605, createdName=lfcmxl, createdTime=Tue Dec 11 12:16:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007516, encodeId=0e9f200e51647, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 28 06:16:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714783, encodeId=05861e1478304, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Thu Jun 07 13:16:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780265, encodeId=b93c1e8026509, content=<a href='/topic/show?id=d8e13080cf' target=_blank style='color:#2F92EE;'>#AZD5363#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3080, encryptionId=d8e13080cf, topicName=AZD5363)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec37461, createdName=szhvet, createdTime=Fri Sep 28 11:16:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710575, encodeId=c57b1e105757f, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Nov 04 23:16:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379156, encodeId=d9a813e91561e, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Fri May 11 11:16:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313901, encodeId=ce3831390188, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Thu May 10 21:59:31 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313758, encodeId=6c18313e580d, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu May 10 08:16:04 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-06-07 12498e5fm22(暂无昵称)

    #AZ#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1653795, encodeId=4e7d1653e95e8, content=<a href='/topic/show?id=b374448088f' target=_blank style='color:#2F92EE;'>#妇科恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44808, encryptionId=b374448088f, topicName=妇科恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=840a24370605, createdName=lfcmxl, createdTime=Tue Dec 11 12:16:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007516, encodeId=0e9f200e51647, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 28 06:16:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714783, encodeId=05861e1478304, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Thu Jun 07 13:16:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780265, encodeId=b93c1e8026509, content=<a href='/topic/show?id=d8e13080cf' target=_blank style='color:#2F92EE;'>#AZD5363#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3080, encryptionId=d8e13080cf, topicName=AZD5363)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec37461, createdName=szhvet, createdTime=Fri Sep 28 11:16:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710575, encodeId=c57b1e105757f, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Nov 04 23:16:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379156, encodeId=d9a813e91561e, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Fri May 11 11:16:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313901, encodeId=ce3831390188, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Thu May 10 21:59:31 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313758, encodeId=6c18313e580d, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu May 10 08:16:04 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-09-28 szhvet

    #AZD5363#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1653795, encodeId=4e7d1653e95e8, content=<a href='/topic/show?id=b374448088f' target=_blank style='color:#2F92EE;'>#妇科恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44808, encryptionId=b374448088f, topicName=妇科恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=840a24370605, createdName=lfcmxl, createdTime=Tue Dec 11 12:16:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007516, encodeId=0e9f200e51647, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 28 06:16:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714783, encodeId=05861e1478304, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Thu Jun 07 13:16:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780265, encodeId=b93c1e8026509, content=<a href='/topic/show?id=d8e13080cf' target=_blank style='color:#2F92EE;'>#AZD5363#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3080, encryptionId=d8e13080cf, topicName=AZD5363)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec37461, createdName=szhvet, createdTime=Fri Sep 28 11:16:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710575, encodeId=c57b1e105757f, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Nov 04 23:16:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379156, encodeId=d9a813e91561e, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Fri May 11 11:16:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313901, encodeId=ce3831390188, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Thu May 10 21:59:31 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313758, encodeId=6c18313e580d, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu May 10 08:16:04 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-11-04 ms6323715314570549

    #PIK3CA突变#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1653795, encodeId=4e7d1653e95e8, content=<a href='/topic/show?id=b374448088f' target=_blank style='color:#2F92EE;'>#妇科恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44808, encryptionId=b374448088f, topicName=妇科恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=840a24370605, createdName=lfcmxl, createdTime=Tue Dec 11 12:16:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007516, encodeId=0e9f200e51647, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 28 06:16:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714783, encodeId=05861e1478304, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Thu Jun 07 13:16:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780265, encodeId=b93c1e8026509, content=<a href='/topic/show?id=d8e13080cf' target=_blank style='color:#2F92EE;'>#AZD5363#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3080, encryptionId=d8e13080cf, topicName=AZD5363)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec37461, createdName=szhvet, createdTime=Fri Sep 28 11:16:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710575, encodeId=c57b1e105757f, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Nov 04 23:16:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379156, encodeId=d9a813e91561e, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Fri May 11 11:16:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313901, encodeId=ce3831390188, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Thu May 10 21:59:31 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313758, encodeId=6c18313e580d, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu May 10 08:16:04 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-05-11 weiz

    #实体肿瘤#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1653795, encodeId=4e7d1653e95e8, content=<a href='/topic/show?id=b374448088f' target=_blank style='color:#2F92EE;'>#妇科恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44808, encryptionId=b374448088f, topicName=妇科恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=840a24370605, createdName=lfcmxl, createdTime=Tue Dec 11 12:16:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007516, encodeId=0e9f200e51647, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 28 06:16:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714783, encodeId=05861e1478304, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Thu Jun 07 13:16:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780265, encodeId=b93c1e8026509, content=<a href='/topic/show?id=d8e13080cf' target=_blank style='color:#2F92EE;'>#AZD5363#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3080, encryptionId=d8e13080cf, topicName=AZD5363)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec37461, createdName=szhvet, createdTime=Fri Sep 28 11:16:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710575, encodeId=c57b1e105757f, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Nov 04 23:16:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379156, encodeId=d9a813e91561e, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Fri May 11 11:16:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313901, encodeId=ce3831390188, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Thu May 10 21:59:31 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313758, encodeId=6c18313e580d, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu May 10 08:16:04 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-05-10 1de11f7fm56(暂无匿称)

    学习了.谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1653795, encodeId=4e7d1653e95e8, content=<a href='/topic/show?id=b374448088f' target=_blank style='color:#2F92EE;'>#妇科恶性肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44808, encryptionId=b374448088f, topicName=妇科恶性肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=840a24370605, createdName=lfcmxl, createdTime=Tue Dec 11 12:16:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007516, encodeId=0e9f200e51647, content=<a href='/topic/show?id=fe2b142e95c' target=_blank style='color:#2F92EE;'>#PIK3CA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14279, encryptionId=fe2b142e95c, topicName=PIK3CA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 28 06:16:00 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714783, encodeId=05861e1478304, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Thu Jun 07 13:16:00 CST 2018, time=2018-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780265, encodeId=b93c1e8026509, content=<a href='/topic/show?id=d8e13080cf' target=_blank style='color:#2F92EE;'>#AZD5363#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3080, encryptionId=d8e13080cf, topicName=AZD5363)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec37461, createdName=szhvet, createdTime=Fri Sep 28 11:16:00 CST 2018, time=2018-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710575, encodeId=c57b1e105757f, content=<a href='/topic/show?id=4ad0142806f' target=_blank style='color:#2F92EE;'>#PIK3CA突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14280, encryptionId=4ad0142806f, topicName=PIK3CA突变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=617b31881621, createdName=ms6323715314570549, createdTime=Sun Nov 04 23:16:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379156, encodeId=d9a813e91561e, content=<a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46021, encryptionId=49ed460213b, topicName=实体肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c77441, createdName=weiz, createdTime=Fri May 11 11:16:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313901, encodeId=ce3831390188, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6b0d1671629, createdName=1de11f7fm56(暂无匿称), createdTime=Thu May 10 21:59:31 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313758, encodeId=6c18313e580d, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Thu May 10 08:16:04 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-05-10 张新亮1853311252142e2fm

    好文献学习了

    0